sitagliptin sandoz 50 mg tabletki powlekane
sandoz gmbh - sitagliptin hydrochloride monohydrate - tabletki powlekane - 50 mg
sitagliptin stada 100 mg tabletki powlekane
stada arzneimittel ag - sitagliptin hydrochloride monohydrate - tabletki powlekane - 100 mg
sitagliptin stada 50 mg tabletki powlekane
stada arzneimittel ag - sitagliptin hydrochloride monohydrate - tabletki powlekane - 50 mg
depepsit met 100 mg + 1000 mg tabletki o zmodyfikowanym uwalnianiu
adamed pharma s.a. - sitagliptin hydrochloride monohydrate + metformini hydrochloridum - tabletki o zmodyfikowanym uwalnianiu - 100 mg + 1000 mg
depepsit met 50 mg + 1000 mg tabletki o zmodyfikowanym uwalnianiu
adamed pharma s.a. - sitagliptin hydrochloride monohydrate + metformini hydrochloridum - tabletki o zmodyfikowanym uwalnianiu - 50 mg + 1000 mg
depepsit met 50 mg + 500 mg tabletki o zmodyfikowanym uwalnianiu
adamed pharma s.a. - sitagliptin hydrochloride monohydrate + metformini hydrochloridum - tabletki o zmodyfikowanym uwalnianiu - 50 mg + 500 mg
sitagliptin accord
accord healthcare s.l.u. - sitagliptin hydrochloride - diabetes mellitus, type 2 - leki stosowane w cukrzycy - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.
sitagliptin bioton 100 mg tabletki powlekane
bioton s.a. - sitagliptin hydrochloride monohydrate - tabletki powlekane - 100 mg
sitagliptin bioton 25 mg tabletki powlekane
bioton s.a. - sitagliptin hydrochloride monohydrate - tabletki powlekane - 25 mg
sitagliptin bioton 50 mg tabletki powlekane
bioton s.a. - sitagliptin hydrochloride monohydrate - tabletki powlekane - 50 mg